Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB; Atrasentan Phase III Study Group Institutions. Carducci MA, et al. Among authors: schulman cc. Cancer. 2007 Nov 1;110(9):1959-66. doi: 10.1002/cncr.22996. Cancer. 2007. PMID: 17886253 Free article. Clinical Trial.
Role of bisphosphonates in prostate cancer.
Saad F, Schulman CC. Saad F, et al. Among authors: schulman cc. Eur Urol. 2004 Jan;45(1):26-34. doi: 10.1016/j.eururo.2003.10.003. Eur Urol. 2004. PMID: 14667511 Review.
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Carducci MA, et al. Among authors: schulman cc. J Clin Oncol. 2003 Feb 15;21(4):679-89. doi: 10.1200/JCO.2003.04.176. J Clin Oncol. 2003. PMID: 12586806 Clinical Trial.
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Raviv G, Zlotta AR, Janssen Th, Descamps F, Vanegas JP, Verhest A, Schulman CC. Raviv G, et al. Among authors: schulman cc. Cancer. 1996 May 15;77(10):2103-8. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2103::AID-CNCR21>3.0.CO;2-Y. Cancer. 1996. PMID: 8640677
Prevention of prostate cancer.
Schulman CC, Zlotta AR. Schulman CC, et al. Recent Results Cancer Res. 2003;163:199-211; discussion 264-6. doi: 10.1007/978-3-642-55647-0_18. Recent Results Cancer Res. 2003. PMID: 12903855 Review.
483 results